Risk factors for Clostridium difficile infection in hemato-oncological patients: A case control study in 144 patients

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Fuereder, Thorsten ^a   Koni, Danjel ^a   Gleiss, Andreas ^a   Kundi, Michael ^a   Makristathis, Athanasios ^a   Zielinski, Christoph ^a   Steininger, Christoph ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT;

ADULT; AGED; CASE CONTROL STUDY; CLOSTRIDIUM INFECTION; COMBINATION DRUG THERAPY; COMPLICATION; CROSS INFECTION; DIARRHEA; FEMALE; HEMATOLOGIC DISEASE; HUMAN; MALE; MICROBIOLOGY; MIDDLE AGED; RETROSPECTIVE STUDY; RISK FACTOR; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CASE-CONTROL STUDIES; CLOSTRIDIUM INFECTIONS; CROSS INFECTION; DIARRHEA; DRUG THERAPY; DRUG THERAPY, COMBINATION; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 84982124176     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep31498     Document Type: Article

References (33)

1. Lessa, F. C., Winston, L. G. & McDonald, L. C. Burden of Clostridium difcile infection in the United States. The New England journal of medicine 372, 2369-2370, doi: 10.1056/NEJMc1505190 (2015).
2. McDonald, L. C., Owings, M. & Jernigan, D. B. Clostridium difcile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerging infectious diseases 12, 409-415, doi: 10.3201/eid1205.051064 (2006).
3. Mizusawa, M., Doron, S. & Gorbach, S. Clostridium difcile Diarrhea in the Elderly: Current Issues and Management Options. Drugs & aging doi: 10.1007/s40266-015-0289-2 (2015).
4. Wiegand, P. N. et al. Clinical and economic burden of Clostridium difcile infection in Europe: a systematic review of healthcare-facility-acquired infection. The Journal of hospital infection 81, 1-14, doi: 10.1016/j.jhin.2012.02.004 (2012).
5. Britton, R. A. & Young, V. B. Role of the intestinal microbiota in resistance to colonization by Clostridium difcile. Gastroenterology 146, 1547-1553, doi: 10.1053/j.gastro.2014.01.059 (2014).
6. Gorschluter, M. et al. Clostridium difcile infection in patients with neutropenia. Clinical infectious diseases: an Official publication of the Infectious Diseases Society of America 33, 786-791, doi: 10.1086/322616 (2001).
7. Anand, A. & Glatt, A. E. Clostridium difcile infection associated with antineoplastic chemotherapy: a review. Clinical infectious diseases: an Official publication of the Infectious Diseases Society of America 17, 109-113 (1993).
8. Al-Tureihi, F. I., Hassoun, A., Wolf-Klein, G. & Isenberg, H. Albumin, length of stay, and proton pump inhibitors: key factors in Clostridium difcile-associated disease in nursing home patients. Journal of the American Medical Directors Association 6, 105-108, doi: 10.1016/j.jamda.2005.01.003 (2005).
9. Chakrabarti, S., Lees, A., Jones, S. G. & Milligan, D. W. Clostridium difcile infection in allogeneic stem cell transplant recipients is associated with severe graf-versus-host disease and non-relapse mortality. Bone marrow transplantation 26, 871-876, doi: 10.1038/sj.bmt.1702627 (2000).
10. Clabots, C. R., Johnson, S., Olson, M. M., Peterson, L. R. & Gerding, D. N. Acquisition of Clostridium difcile by hospitalized patients: evidence for colonized new admissions as a source of infection. The Journal of infectious diseases 166, 561-567 (1992).
11. Hornbuckle, K. et al. Determination and validation of a predictive model for Clostridium difcile diarrhea in hospitalized oncology patients. Annals of oncology: Official journal of the European Society for Medical Oncology/ESMO 9, 307-311 (1998).
12. Fekety, R. et al. Recurrent Clostridium difcile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial. Clinical infectious diseases: an Official publication of the Infectious Diseases Society of America 24, 324-333 (1997).
13. Raza, S., Baig, M. A., Russell, H., Gourdet, Y. & Berger, B. J. Clostridium difcile infection following chemotherapy. Recent patents on anti-infective drug discovery 5, 1-9 (2010).
14. Kamthan, A. G., Bruckner, H. W., Hirschman, S. Z. & Agus, S. G. Clostridium difcile diarrhea induced by cancer chemotherapy. Archives of internal medicine 152, 1715-1717 (1992).
15. Emoto, M., Kawarabayashi, T., Hachisuga, M. D., Eguchi, F. & Shirakawa, K. Clostridium difcile colitis associated with cisplatin-based chemotherapy in ovarian cancer patients. Gynecologic oncology 61, 369-372 (1996).
16. Nielsen, H., Daugaard, G., Tvede, M. & Bruun, B. High prevalence of Clostridium difcile diarrhoea during intensive chemotherapy for disseminated germ cell cancer. British journal of cancer 66, 666-667 (1992).
17. Husain, A., Aptaker, L., Spriggs, D. R. & Barakat, R. R. Gastrointestinal toxicity and Clostridium difcile diarrhea in patients treated with paclitaxel-containing chemotherapy regimens. Gynecologic oncology 71, 104-107, doi: 10.1006/gyno.1998.5158 (1998).
18. Stewart, D. B., Yacoub, E. & Zhu, J. Chemotherapy patients with C. difcile colitis have outcomes similar to immunocompetent C. difcile patients. Journal of gastrointestinal surgery: Official journal of the Society for Surgery of the Alimentary Tract 16, 1566-1572, doi: 10.1007/s11605-012-1930-6 (2012).
19. Giford, A. H. & Kirkland, K. B. Risk factors for Clostridium difcile-associated diarrhea on an adult hematology-oncology ward. European journal of clinical microbiology & infectious diseases: Official publication of the European Society of Clinical Microbiology 25, 751-755, doi: 10.1007/s10096-006-0220-1 (2006).
20. Loo, V. G. et al. Host and pathogen factors for Clostridium difcile infection and colonization. The New England journal of medicine 365, 1693-1703, doi: 10.1056/NEJMoa1012413 (2011).
21. Debast, S. B., Bauer, M. P. & Kuijper, E. J. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difcile infection. Clinical microbiology and infection: the Official publication of the European Society of Clinical Microbiology and Infectious Diseases 20 Suppl 2, 1-26, doi: 10.1111/1469-0691.12418 (2014).
22. Pancholi, P., Kelly, C., Raczkowski, M. & Balada-Llasat, J. M. Detection of Toxigenic Clostridium difcile: Comparison of the Cell Culture Neutralization, Xpert C. difcile, Xpert C. difcile/Epi, and Illumigene C. difcile Assays. Journal of Clinical Microbiology 50, 1331-1335, doi: 10.1128/jcm.06597-11 (2012).
23. Vindigni, S. M. & Surawicz, C. M. C. Difficile Infection: Changing Epidemiology and Management Paradigms. Clinical and translational gastroenterology 6, e99, doi: 10.1038/ctg.2015.24 (2015).
24. Dubberke, E. R. et al. Clostridium difcile-associated disease in a setting of endemicity: identifcation of novel risk factors. Clinical infectious diseases: an Official publication of the Infectious Diseases Society of America 45, 1543-1549, doi: 10.1086/523582 (2007).
25. Heard, S. R., Wren, B., Barnett, M. J., Tomas, J. M. & Tabaqchali, S. Clostridium difcile infection in patients with haematological malignant disease. Risk factors, faecal toxins and pathogenic strains. Epidemiology and infection 100, 63-72 (1988).
26. Rodriguez Garzotto, A. et al. Risk factors associated with Clostridium difcile infection in adult oncology patients. Supportive care in cancer: Official journal of the Multinational Association of Supportive Care in Cancer 23, 1569-1577, doi: 10.1007/s00520-014-2506-7 (2015).
27. Bloomfeld, M. G., Sherwin, J. C. & Gkrania-Klotsas, E. Risk factors for mortality in Clostridium difcile infection in the general hospital population: a systematic review. The Journal of hospital infection 82, 1-12, doi: 10.1016/j.jhin.2012.05.008 (2012).
28. Keefe, D. M., Brealey, J., Goland, G. J. & Cummins, A. G. Chemotherapy for cancer causes apoptosis that precedes hypoplasia in crypts of the small intestine in humans. Gut 47, 632-637 (2000).
29. Wardill, H. R. et al. Irinotecan disrupts tight junction proteins within the gut: implications for chemotherapy-induced gut toxicity. Cancer biology & therapy 15, 236-244, doi: 10.4161/cbt.27222 (2014).
30. Montassier, E. et al. Chemotherapy-driven dysbiosis in the intestinal microbiome. Alimentary pharmacology & therapeutics 42, 515-528, doi: 10.1111/apt.13302 (2015).
31. Kelly, C. P., Pothoulakis, C. & LaMont, J. T. Clostridium difcile colitis. The New England journal of medicine 330, 257-262, doi: 10.1056/nejm199401273300406 (1994).
32. Bauer, M. P. et al. Renal failure and leukocytosis are predictors of a complicated course of Clostridium difcile infection if measured on day of diagnosis. Clinical infectious diseases: an Official publication of the Infectious Diseases Society of America 55 Suppl 2, S149-S153, doi: 10.1093/cid/cis340 (2012).
33. Cloud, J., Noddin, L., Pressman, A., Hu, M. & Kelly, C. Clostridium difcile strain NAP-1 is not associated with severe disease in a nonepidemic setting. Clinical gastroenterology and hepatology: the Official clinical practice journal of the American Gastroenterological Association 7, 868-873 e862, doi: 10.1016/j.cgh.2009.05.018 (2009).